New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:23 EDTCBSTCubist Sivextro sales to benefit from lack of warnings, says JMP Securities
After the FDA approved Cubist's Sivextro treatment for skin infections, JMP Securities notes that the FDA did not require warnings about a number of potential serious side effects to be placed on the drug's label. The firm thinks the absence of these warnings should boost sales of the drug. It reiterates an Outperform rating on Cubist.
News For CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CBST

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use